454 Life Sciences, a Roche Company, announced at the Association of Molecular Pathology Annual Meeting in Kissimmee, Florida a series of revolutionary developments which significantly expand the company’s high-throughput sequencing portfolio. Addressing the growing demand for next-generation sequencing data in everyday biological and clinical research, the company revealed the new GS Junior System, an affordable bench top sequencing platform slated for release in 2010.
The GS Junior System, which is no bigger than a typical laser printer, has performance and features tuned to fit the needs of small to medium sized laboratories. The platform will launch with long-read GS Junior Titanium chemistry, offering 400 – 500 bp read lengths, and will be shipped with a desktop computer that is optimized for GS Junior Run processing and downstream data analysis. “With the GS Junior System, we are extremely excited to make next-generation sequencing readily available to the individual researcher, just as the PC brought computing to the masses,” said Christopher McLeod, president and CEO of 454 Life Sciences. “This truly enabling technology is now affordable for nearly every research lab. At the same time, we continue to extend the performance of our flagship Genome Sequencer FLX System.”
The company announced plans to initiate an early access program for development of the next set of performance improvements to the Genome Sequencer FLX System, which will double the read length of the current GS FLX Titanium Kits and expect to contain reads up to 1,000 bp. The DOE Joint Genome Institute will be the first site to begin early access later this month and will use the long-read chemistries to sequence a variety of large, complex genomes. Additional early access partners are expected to be announced in the near future.
“The value of our longer read lengths, coupled with the latest advances in our assembler software, have been demonstrated by the successful conclusion of a number of recent de novo sequencing projects, such as the cod fish genome,” explained Michael Egholm, CTO and vice president of R&D of 454 Life Science. “The Genome Sequencer FLX System provides a robust platform to sequence and assemble nearly any size genome quickly, without the need for supplementary Sanger data.”
The company’s final announcement at the event was the launch and immediate availability of several new kits, protocols and software updates for the Genome Sequencer FLX System. The new products enable two new major application areas to take advantage of the long 400-500 bp reads and increased density of the GS FLX Titanium series chemistry—transcriptome sequencing and amplicon (PCR product) sequencing. Additional product updates highlight the company’s continued efforts to ease workflow, including a new Rapid Library Preparation Kit which takes around half of the time and requires significantly less input DNA, and a set of 12 Rapid Library Multiplex Identifier (MID) Adaptors for sample pooling.
Significant improvements to the complete suite of GS Data Analysis Software are evident in the new GS De Novo Assembler software, now capable of processing data sets from human-sized genomes (3Gb) and transcriptomes. Together the new cDNA sequencing protocol and assembler software offer a complete solution for de novo transcriptome sequencing and analysis, enabling a comprehensive picture of the gene space of nearly any organism, even previously uncharacterized species.
“We are finding that the long EST reads generated by the Genome Sequencer FLX System often readily span multiple exons and are aligned with a high degree of uniqueness when analyzed with our new transcriptome assembler software,” said Egholm. “We believe this solution will yield significant advantages over existing approaches due to the ease of assembly and the ability to characterize alternatively spliced transcripts for a wide range of organisms, without the need for a reference.”
Finally, the latest set of GS FLX Titanium Kits include a new solution for targeted amplicon sequencing applications, now supporting ultra-deep sequencing of long 400 bp amplicons. “Amplicon sequencing with the Genome Sequencer FLX System has paved the way for important medical research over the past few years, including detection of low-frequency drug-resistance variants in HIV-infected samples, and high-resolution HLA sequencing and typing,” explained McLeod. “GS FLX Titanium Amplicon sequencing will push these studies to the next level by allowing amplicon designs similar to those currently used in Sanger amplicon sequencing, with the additional benefit of up to 1 million clonal reads per run.”